Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09), Zacks reports. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.39 million.
Eyepoint Pharmaceuticals Stock Up 4.7%
Shares of Eyepoint Pharmaceuticals stock traded up $0.58 on Thursday, hitting $12.83. The stock had a trading volume of 2,237,980 shares, compared to its average volume of 1,280,019. Eyepoint Pharmaceuticals has a twelve month low of $9.65 and a twelve month high of $19.11. The business’s 50 day moving average is $13.12 and its two-hundred day moving average is $13.79. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -3.67 and a beta of 1.76.
Institutional Trading of Eyepoint Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in EYPT. Russell Investments Group Ltd. acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at $76,000. Tower Research Capital LLC TRC lifted its holdings in shares of Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Eyepoint Pharmaceuticals in the fourth quarter valued at about $98,000. Finally, Raymond James Financial Inc. boosted its position in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after acquiring an additional 1,177 shares during the period. 99.41% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on EYPT
About Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Featured Stories
- Five stocks we like better than Eyepoint Pharmaceuticals
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
